Daewon Pharmaceutical's P-CAB new drug 'Fadoprazan' proves efficacy and safety in Phase 3 clinical trial
Predicted impact: Medium
Phase 3 success for a drug is significant but was already reported and surged shares.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.